- Solar park can generate up to 40% of the energy needs at its 5-hectare facility in Doima, Colombia
- Project demonstrates Khiron’s commitment to sustainability by reducing its carbon footprint by approximately 7 tons of CO2 a year, while decreasing operational energy costs
TORONTO, June 24, 2020 /CNW/ – Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, announces the completed installation of a state-of-the-art 2,600 panel solar park that will generate electricity to power the Company’s production facility in Doima, Colombia.
Developed with ReFeel, a leading Italian renewable Company with more than 80 MW installed in Europe and Latin America, Khiron’s solar park is expected to generate up to 700 kWh through a photovoltaic (PV) system that comprises 2,618 installed solar panels. With the construction of the PV system, Khiron can self-generate up to 40% of the energy it needs for day-to-day facility operations and is expected to reduce CO2 emissions by 570 tons a year.
“Installation of the solar park at our Doima production facility brings Khiron exponential efficiencies, allowing us to significantly reduce operational energy costs and benefit from tax reductions, as we actively commit to deploying sustainability initiatives across our operations,” comments Khiron CEO and Director Alvaro Torres. “We’re proud to take actions aimed at sharply reducing greenhouse gas emissions and making this contribution to help counter the global environmental challenge.”
The solar park project delivered direct employment to a team of 20 personnel in the local Doima community and provided access to globally recognized solar energy technical training in PV systems and renewable energy installations, enhancing the teams future participation in projects of the same type, at a regional and national level. “We are continuing to support the Doima community, improving resource and waste management in the area as part of our company-wide sustainability program,” continues, Mr. Torres.
View the Khiron facilities image portfolio at: https://investors.khiron.ca/media-room/facilities
About Khiron Life Sciences Corp.
Khiron is a vertically integrated medical and CPG cannabis company with core operations in Latin America, and operational activity in Europe and North America. Khiron is the leading cannabis company in Colombia and the first company licensed in Colombia for the cultivation, production, domestic distribution, and international export of both low and high THC medical cannabis products. The Company has presence in Mexico, Peru, Uruguay, Brazil, UK and Germany, where it is positioned to begin sales of medical cannabis.
Leveraging its first-mover advantage, and patient oriented approach, Khiron combines global scientific expertise, product innovation, agricultural infrastructure, wholly-owned medical clinics, and online doctor education programs to drive prescription and brand loyalty to address priority medical conditions. Its Wellbeing unit launched the first branded CBD skincare brand in Colombia, with Kuida now marketed in multiple jurisdictions in Latin America, the US and UK. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors
This press release may contain certain “forward-looking information” and “forward-looking statements” within the meaning of applicable securities legislation. All information contained herein that is not historical in nature may constitute forward-looking information. Khiron undertakes no obligation to comment analyses, expectations or statements made by third-parties in respect of Khiron, its securities, or financial or operating results (as applicable). Although Khiron believes that the expectations reflected in forward-looking statements in this press release are reasonable, such forward-looking statement has been based on expectations, factors and assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain of which are beyond Khiron’s control, including the risk factors discussed in Khiron’s Annual Information Form which is available on Khiron’s SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is expressly qualified by this cautionary statement and are made as of the date hereof. Khiron disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking information, whether as a result of new information, future events or otherwise.
Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.
SOURCE Khiron Life Sciences Corp.